Denmark is still the only country in Europe Countries that does not provide Spinraza as a standard therapy to its patients. SMA1 children without respiratory assistance and SMA2 children up to the age of six have access.
New data suggest that older childrens and adults with SMA2 and SMA3 may benefit of Spinraza. We report already here
- Potentiell biomarkör identifierad för SMA
- SMA Typ 1-3: Biogen continues with new data in adults and infants
We do not want to spread out euphoria. We remain skeptical as to whether the Danes can handle the third attempt and finally approve the drug. Denmark has several times disappointed its SMA patients, but Biogen confirms the development of the case